

## **Claims**

5

35

- 1. A method for the treatment or prophylaxis of disorders in which the overproduction of s-CD23 is implicated, which method comprises the administration of an effective amount of an inhibitor of the formation of human soluble CD23 to a human or non-human mammal in need thereof, with the provisos that:
- (a) the disorder is not mediated by a matrix metalloprotease or by tissue necrosis factor; and
- (b) the inhibitor does not form part of the state of the art by virtue of WO92/16517 or WO93/18173.
  - 2. The method according to Claim 1, wherein the inhibitor of the formation of s-CD23 is an inhibitor of matrix metalloprotease.
- 15 3. The method according to Claim 1, wherein the inhibitor of the formation of s-CD23 is a hydroxamic acid derivative, a phosphate or a thiol.
  - 4. The method according to Claim 1, wherein the inhibitor of the formation of s-CD23 is selected from:
- 20 [4-(N-hydroxyamino)-2-(R)-isobutyl-3-(S)-(2-thiophenethiomethyl)succinyl]-(S)-phenylalanine-N-methylamide;
  - N<sup>2</sup>-[(R)-[hydroxycarbamoylmethyl]-4-methylvaleryl]-N<sup>1</sup>, 3-dimethyl-(S)-valinamide;
- N-[3-(N'-hydroxycarboxamido)-2-(2-methylpropyl)propanoyl]-(S)-O-methyl-25 L-tyrosine-N-methylamide;
  - methyl 3-(S)-mercapto-6-methyl-4-(S)-[[[1(S)-[(methylamino)carbonyl]-2-(3-indolyl)ethyl]amino]carbonyl]heptanoate;
  - isopropyl 3-(S)-mercapto-6-methyl-4-(S)-[[[1(S)-[(methylamino)carbonyl]-2-(3-indolyl)ethyl]amino]carbonyl]heptanoate;
- 30 3-(S)-mercapto- $N^1$ -[1-(S)-[(methylamino)carbonyl]-2-(4-methoxyphenyl)ethyl]-2-(S)-(2-methylpropyl)pentanediamide;
  - $\underline{N}$ -[ $\underline{N}$ -((S)-1-phosphonopropyl)-(S)-leucyl]- $\underline{O}$ -methyl-(S)-tyrosine  $\underline{N}$ -methylamide;
  - N-[3-(hydroxycarboxamido)-2R-(2-methylpropyl)propanoyl]-(S)-phenylalanine-N-methylamide; and
    - N-[3-(hydroxycarboxamido)-2R-(2-methylpropyl)propanoyl]-(S)-phenylalanine-N-benzylamide; or a pharmaceutically acceptable salts thereof.



5. The method according to Claim 1, wherein the inhibitor is hereinbefore described with reference to the Table.

5